However, considering the immune-excluded phenotype of NRC3, patients in NRC3 might display ineffective response to anti- PD-1/PD- L1 treatment, which might partially explain why high expression of PD-1/PD-L1 has not been clinically demonstrated to effectively predict immunotherapy response in CRC. This evidence concerns the gene CD274 and colorectal carcinoma.